{
    "root": "36374dfa-9673-12ef-e063-6294a90a5369",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Paclitaxel",
    "value": "20250528",
    "ingredients": [
        {
            "name": "ALBUMIN HUMAN",
            "code": "ZIF514RVZR"
        },
        {
            "name": "PACLITAXEL",
            "code": "P88XT4IS4D"
        }
    ],
    "indications": "Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. (1.1) Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. (1.2) Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. (1.3)",
    "contraindications": "Do not substitute paclitaxel protein-bound particles for injectable suspension (albumin-bound) for other paclitaxel products. (2.1) Extravasation: Closely monitor the infusion site for extravasation and infiltration. (2.1) Metastatic Breast Cancer (MBC): Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 260 mg/m2 intravenously over 30 minutes every 3 weeks. (2.2) Non-Small Cell Lung Cancer (NSCLC): Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 100 mg/m2 intravenously over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after paclitaxel protein-bound particles for injectable suspension (albumin-bound). (2.2) Adenocarcinoma of the Pancreas: Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 125 mg/m2 intravenously over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle; administer gemcitabine on Days 1, 8, and 15 of each 28-day cycle immediately after paclitaxel protein-bound particles for injectable suspension (albumin-bound). (2.4) Use in Patients with Hepatic Impairment: Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is not recommended for use in patients with AST > 10 x ULN; or bilirubin > 5 x ULN or with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment. For MBC or NSCLC, reduce starting dose in patients with moderate to severe hepatic impairment. (2.5) Dose Reductions for Adverse Reactions: Dose reductions or discontinuation may be needed based on severe hematologic, neurologic, cutaneous, or gastrointestinal toxicities. (2.6)",
    "warningsAndPrecautions": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a white to yellow, sterile lyophilized powder supplied as:\n                  NDC: 0781-3531-91 100 mg of paclitaxel in a single-dose vial, individually packaged in a carton.",
    "adverseReactions": "Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is contraindicated in patients with:\n                  \n                     Baseline neutrophil counts of < 1,500 cells/mm\n   3\n                        [see \n    Warnings and Precautions (5.1)]\n   \n                     \n                     A history of severe hypersensitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound) \n   [see \n    Warnings and Precautions (5.5)]"
}